Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia.
Sawa M, Miyamoto T, Kim HJ, Hiramatsu Y, Cheong JW, Ikezoe T, Naoe T, Akashi K, Morita S, Kosako M, Ikegaya M, Terada W, Kadokura T, Hill J, Miyawaki S, Gill SC, Heinloth A, Hasabou N. Sawa M, et al. Among authors: miyamoto t. Int J Hematol. 2024 Nov 6. doi: 10.1007/s12185-024-03840-x. Online ahead of print. Int J Hematol. 2024. PMID: 39503987
IKZF1plus alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial.
Ito Y, Ozawa H, Eto T, Miyamoto T, Kamimura T, Ogawa R, Uchida N, Wake A, Fujisaki T, Ohno Y, Takase K, Okumura H, Takamatsu Y, Kawano N, Akashi K, Nagafuji K. Ito Y, et al. Among authors: miyamoto t. Eur J Haematol. 2023 Jul;111(1):103-112. doi: 10.1111/ejh.13972. Epub 2023 Apr 8. Eur J Haematol. 2023. PMID: 36991564
Late mortality and causes of death among long-term survivors after autologous hematopoietic stem cell transplantation.
Iida M, Nakasone H, Yamashita T, Inoue M, Ishida Y, Uchiyama H, Katayama Y, Miyamoto T, Yoshioka S, Shiratori S, Mori T, Sawa M, Sugio Y, Fukuda T, Ichinohe T, Atsuta Y, Inamoto Y; Late Effect and Quality of Life Working Group of the Japan Society for Hematopoietic Cell Transplantation. Iida M, et al. Among authors: miyamoto t. Blood Cell Ther. 2020 Feb 25;3(1):11-17. doi: 10.31547/bct-2019-011. eCollection 2020 Feb 25. Blood Cell Ther. 2020. PMID: 37465377 Free PMC article.
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
Mori Y, Takizawa J, Katsuoka Y, Takezako N, Nagafuji K, Handa H, Kuroda J, Sunami K, Kamimura T, Ogawa R, Kikushige Y, Harada M, Akashi K, Miyamoto T; Japan Study Group for Cell Therapy and Transplantation. Mori Y, et al. Among authors: miyamoto t. Cancer Sci. 2024 Jun;115(6):2002-2011. doi: 10.1111/cas.16158. Epub 2024 Mar 18. Cancer Sci. 2024. PMID: 38498976 Free PMC article. Clinical Trial.
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, Tateishi U, Miyamoto T, Matsuda Y, Ishikawa J, Rai S, Takahashi T, Yamauchi T, Matsumura I, Akashi K, Kanakura Y, Suzumiya J. Kato K, et al. Among authors: miyamoto t. Int J Hematol. 2024 Jun;119(6):677-685. doi: 10.1007/s12185-024-03738-8. Epub 2024 Mar 22. Int J Hematol. 2024. PMID: 38519820 Clinical Trial.
Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.
Matsumura I, Ohtake S, Atsuta Y, Kurata M, Minami Y, Takahashi N, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Ono T, Okada M, Tauchi T, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Asou N, Naoe T, Kiyoi H, Miyazaki Y. Matsumura I, et al. Among authors: miyamoto t. Blood Adv. 2024 Oct 22;8(20):5237-5247. doi: 10.1182/bloodadvances.2024012655. Blood Adv. 2024. PMID: 38968156 Free PMC article. Clinical Trial.
4,198 results